These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31028406)

  • 1. Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.
    Back M; Jayamanne D; Brazier D; Newey A; Bailey D; Schembri G; Hsiao E; Khasraw M; Wong M; Kastelan M; Brown C; Wheeler H
    Strahlenther Onkol; 2020 Jan; 196(1):31-39. PubMed ID: 31028406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.
    Back M; Jayamanne DT; Brazier D; Newey A; Bailey D; Schembri GP; Hsiao E; Khasraw M; Wong M; Kastelan M; Guo L; Clarke S; Wheeler H
    J Med Imaging Radiat Oncol; 2019 Apr; 63(2):272-280. PubMed ID: 30677248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma.
    Back M; Jayamanne D; Brazier D; Bailey D; Hsiao E; Guo L; Wheeler H
    J Clin Neurosci; 2019 Jan; 59():68-74. PubMed ID: 30446361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Volumetric Response and Survival of Patients With Bulky IDH-Mutated Grade 3 Glioma Managed With FET-FDG-Guided Integrated Boost IMRT.
    Mills D; Horsley P; Venkatasha V; Back M
    Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):343-352. PubMed ID: 38553362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region following radiotherapy.
    Metz G; Jayamanne D; Wheeler H; Wong M; Cook R; Little N; Parkinson J; Kastelan M; Brown C; Back M
    BMC Neurol; 2022 Jan; 22(1):24. PubMed ID: 35027006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing radiation dose to normal brain through a risk adapted dose reduction protocol for patients with favourable subtype anaplastic glioma.
    Back M; LeMottee M; Crasta C; Bailey D; Wheeler H; Guo L; Eade T
    Radiat Oncol; 2017 Mar; 12(1):46. PubMed ID: 28253929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.
    Kizilbash SH; Giannini C; Voss JS; Decker PA; Jenkins RB; Hardie J; Laack NN; Parney IF; Uhm JH; Buckner JC
    J Neurooncol; 2014 Oct; 120(1):85-93. PubMed ID: 24993250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.
    Jiang H; Ren X; Cui X; Wang J; Jia W; Zhou Z; Lin S
    Neuro Oncol; 2013 Jun; 15(6):775-82. PubMed ID: 23486687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic glioma.
    Back MF; Jayamanne D; Back E; Kastelan M; Khasraw M; Wong M; Brown C; Wheeler H
    Cancer; 2019 Oct; 125(19):3457-3466. PubMed ID: 31251406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].
    Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N
    Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117
    [No Abstract]   [Full Text] [Related]  

  • 11. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
    Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
    World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo Metabolic Profiles as Determined by
    Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U
    Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT.
    Sutera P; Kalash R; Flickinger J; Engh J; Heron DE
    Am J Clin Oncol; 2019 Jan; 42(1):27-35. PubMed ID: 29912004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival, Prognostic Factors, and Volumetric Analysis of Extent of Resection for Anaplastic Gliomas.
    Hong JB; Roh TH; Kang SG; Kim SH; Moon JH; Kim EH; Ahn SS; Choi HJ; Cho J; Suh CO; Chang JH
    Cancer Res Treat; 2020 Oct; 52(4):1041-1049. PubMed ID: 32324987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.
    Reuss DE; Mamatjan Y; Schrimpf D; Capper D; Hovestadt V; Kratz A; Sahm F; Koelsche C; Korshunov A; Olar A; Hartmann C; Reijneveld JC; Wesseling P; Unterberg A; Platten M; Wick W; Herold-Mende C; Aldape K; von Deimling A
    Acta Neuropathol; 2015 Jun; 129(6):867-73. PubMed ID: 25962792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas.
    McNamara MG; Jiang H; Lim-Fat MJ; Sahebjam S; Kiehl TR; Karamchandani J; Coire C; Chung C; Millar BA; Laperriere N; Mason WP
    Can J Neurol Sci; 2017 May; 44(3):288-294. PubMed ID: 28488951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas.
    Cho KH; Kim JY; Lee SH; Yoo H; Shin SH; Moon SH; Kim TH; Shin KH; Yoon M; Lee DH; Pyo HR
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):390-7. PubMed ID: 20097489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
    Esteyrie V; Dehais C; Martin E; Carpentier C; Uro-Coste E; Figarella-Branger D; Bronniman C; Pouessel D; Ciron DL; Ducray F; Moyal EC; Network P
    Oncologist; 2021 May; 26(5):e838-e846. PubMed ID: 33524191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts].
    Wick W; Weller M
    Nervenarzt; 2010 Aug; 81(8):928-30, 932-5. PubMed ID: 20635074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
    Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.